Differentiating Factors Between Erythropoiesis-Stimulating AgentsA Guide to Selection for Anaemia of Chronic Kidney Disease

被引：0
|
作者：
Robert Deicher
Walter H. Hörl
机构：
[1] University of Vienna,Division of Nephrology and Dialysis, Department of Medicine III
[2] Universitätsklinik für Innere Medizin III,Klinische Abteilung für Nephrologie und Dialyse
来源：
Drugs | 2004年 / 64卷
关键词：
Chronic Kidney Disease; Subcutaneous Administration; Peritoneal Dialysis Patient; Sialic Acid Residue; Erythropoiesis Stimulate Agent;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Endogenous erythropoietin (EPO) consists of a central polypeptide core covered by post-translationally linked carbohydrates. Three of the four currently available erythropoiesis stimulating agents (ESA) — epoetin-α, epoetin-β and epoetin-ω — are composed of an identical amino acid sequence, but glycosylation varies as a result of type- and host cell-specific differences in the production process.
引用
收藏
页码：499 / 509
页数：10
相关论文
共 50 条
  • [31] Intersecting Guidelines: Administering Erythropoiesis-Stimulating Agents to Chronic Kidney Disease Patients with Cancer
    Bennett, Charles L.
    Becker, Pamela S.
    Kraut, Eric H.
    Samaras, Athena T.
    West, Dennis P.
    SEMINARS IN DIALYSIS, 2009, 22 (01) : 1 - 4
  • [32] Effect of erythropoiesis-stimulating agents on Healthcare utilization, costs, and outcomes in chronic kidney disease
    Maddux, Franklin W.
    Shetty, Sharashchandra
    Del Aguila, Michael A.
    Nelson, Michael A.
    Murray, Brian M.
    ANNALS OF PHARMACOTHERAPY, 2007, 41 (11) : 1761 - 1769
  • [33] The Safety of Erythropoiesis-Stimulating Agents for the Treatment of Anemia Resulting from Chronic Kidney Disease
    Roberto Robles, Nicolas
    CLINICAL DRUG INVESTIGATION, 2016, 36 (06) : 421 - 431
  • [34] Erythropoiesis-stimulating agents, hypertension and left ventricular hypertrophy in the chronic kidney disease patient
    Schmid, Holger
    Schiffl, Helmut
    Lederer, Stephan R.
    CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, 2011, 20 (05): : 465 - 470
  • [35] Erythropoiesis-stimulating agents increase the risk of acute stroke in patients with chronic kidney disease
    Seliger, Stephen L.
    Zhang, Amy D.
    Weir, Matthew R.
    Walker, Loreen
    Hsu, Van Doren
    Parsa, Afshin
    Diamantidis, Clarissa J.
    Fink, Jeffrey C.
    KIDNEY INTERNATIONAL, 2011, 80 (03) : 288 - 294
  • [36] The Safety of Erythropoiesis-Stimulating Agents for the Treatment of Anemia Resulting from Chronic Kidney Disease
    Nicolas Roberto Robles
    Clinical Drug Investigation, 2016, 36 : 421 - 431
  • [37] Hypogonadism in Males with Chronic Kidney Disease: Another Cause of Resistance to Erythropoiesis-Stimulating Agents?
    Stenvinkel, Peter
    Barany, Peter
    PERITONEAL DIALYSIS - STATE-OF-THE-ART 2012, 2012, 178 : 35 - 39
  • [38] Erythropoiesis-stimulating Agents and Anemia in Patients with Non-dialytic Chronic Kidney Disease
    Kim, Sun Moon
    Kim, Kyeong Min
    Kwon, Soon Kil
    Kim, Hye-Young
    JOURNAL OF KOREAN MEDICAL SCIENCE, 2016, 31 (01) : 55 - 60
  • [39] Erythropoiesis-Stimulating Agents in the Management of Anemia in Chronic Kidney Disease or Cancer: A Historical Perspective
    Aapro, Matti
    Gascon, Pere
    Patel, Kashyap
    Rodgers, George M.
    Fung, Selwyn
    Arantes, Luiz H., Jr.
    Wish, Jay
    FRONTIERS IN PHARMACOLOGY, 2019, 9
  • [40] The economic realities of erythropoiesis-stimulating agent therapy in kidney disease
    Wish, J. B.
    KIDNEY INTERNATIONAL, 2006, 70 : S21 - S25
12345